The FDA has approved a five-day dosing regimen for Dacogen (decitabine for injection, from Eisai) to treat patients with myelodysplastic syndromes (MDS).

The FDA has approved Trelstar 22.5mg (triptorelin pamoate for injectable suspension, from Watson) for the palliative treatment of advanced prostate cancer.

The FDA, Cangene, and Baxter have notified healthcare professionals that cases of intravascular hemolysis (IVH) and its complications have been reported in patients treated for immune thrombocytopenic purpura (ITP) with WinRho SDF [Rho(D) immune globulin IV (human)].

The FDA has approved CSL Behring's Hizentra (immune globulin [human] 20% liquid for subcutaneous injection) for the once weekly treatment of primary immunodeficiency.

The FDA has approved a generic version of Flomax (tamsulosin HCl capsules, from Boehringer Ingelheim) for the treatment of benign prostatic hyperplasia (BPH).